The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
7Biosciences are selling our standard test at €10
It's open platform Shaun. I could bore you to death about MyGo Q16/32
Roche must be very sad they tried to encroach on IT-Is patents and wronged their agreement from 2014. They had a bad divorce.
https://www.genomeweb.com/pcrsample-prep/it-lawsuits-versus-roche-focus-lightcycler-qpcr-instrument?utm_source=TrendMD&utm_medium=TrendMD&utm_campaign=0&trendmd-shared=0#.X4hlurco8Uo
Novacyt and IT-Is had a lovely marriage and then two become on. Pays to be good to the little man, cause you never know one day they may sell you a business for £10m that you can sell £600m test kits off the back of it with a bit of simple PROmate
:-)
I screen shotted the sexy bits
I rarely, say, but it was a good day to top up :-)
https://twitter.com/DopeinkInvest/status/1351633127534424069?s=19
#NCYT's PROmate taking the ? out of testing
Extract & test RNA with or without Class II Biosafety Caninets
Lab technicians & NHS staff all around will be celebrating
#ALNOV #Novacyt
PrimerdesignLtd massive congratulations
When a song says it all. Come on all patient holders, we're on the verge of everything being alright :-)
https://youtu.be/RySHMuLN4Jg
Deeks as we know ain't a fan and DHSC also not giving backing for devises to be used outside of the approved terms of reference, just symptomatic screening
https://twitter.com/deeksj/status/1351586258938691586?s=19
It could be that Antigen LFTs struggle to bind to the mutated S gene Spike Protein outer casing. Check out linked image, works like a lock and key set up, much like encryption for computer buffs, the more mutations the less less likely the spike proteins will bind the LFT agent. We could be in the final days of LFTs as we know them imo
Shaun I previously shared the MyGo and Q16&32 are the same, all that separates them is a sticker and Novacyt back end software adjustments. This is how the former IT-IS CEO explained into me
Deas999 post of 2021 high-five
CAR-T is an informed guess. Is the direction of travel with COVID but more importantly Cancer. I'm aware of interest, maybe I'm a match maker. No certainties but if it happens people can thank me a little :-)
To follow on from last message, unless there's a mutation in ORF1 our core test is a OK
We have the two gene test which looks at ORF1 and S gene. This will likely need a tweek, maybe VariPlex. The dropping out of S gene during analysis will signal that a mutation has occurred. Will still present a postive result as ORF1 will come back as postive
Nitrokev for reference the mutations to virus are occurring within the S gene which is the outer casing of the virus.
Our primary test checks the ORF1 gene which hasn't been affected by mutations. A mutation to ORF1 structure would likely be counterproductive to replication of virus so unlikely to prosper
Hope this makes senses, is second hand info via my geneticist buddy
Have tweeted image of virus for you, plus an interesting article on S gene mutation
https://twitter.com/DopeinkInvest/status/1351557226901725184?s=19
. Sales update
. PROmate unlocks NHS Q16&32 Phase 2
. PROmate could unlock Carr Home Q16&32 contrat
. PROmate Airport testing with Q16&32 with smaller airports
. Antibody ELISA test for vaccine roll out
. Lighthouse Labs renewal / share of £22b Tender
. Maybe we hear about a CAR-T cell acquisition ;-) (COVID & cancer testing)
PROmate and magic beans. Phase ii taking off soon :-)
Excellent news Dean
Much appreciated Hartlebury
"As the UK’s test-before-travel scheme took effect, passengers have been turned away from a transatlantic flight because the airline did not regard their negative Covid tests as sufficiently high standard"
Could you share text for those without Apple to see please?
Makes for interesting reading, i won't name names
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/removal-lists-tests-should-no-longer-be-used-andor-distributed-covid-19-faqs-testing-sars-cov-2
Sales accounted up to year end will be reported (31/12), I assume £100m to £150m of the Q contact in 2020.
For 2021 if company want to be taken seriously by institutional investors Novacyt should move to quarterly reporting and issue 2021 guidance.
We can seek out supplementary proxy guidance from the foklqikg supplementary proxy forecasts from the following companies guidance:
Abbott - 27th jan
PerkinElmer - 2nd Feb
Thermo Fisher - 1st Feb
Roche - 4th feb
Dope :-)
Trilla the Q16&32 NHS contract was a minimum of £150m starting from end sep for 14 weeks.
This would be accounted for up to end December. It would seem roll out was a little slower, but we know 2/3 of the 300 units were deployed by December 3rd. So likely a small amount of the £150 rolls into early 2021
A potential £100m was scheduled over next 10 weeks, taking cumulative value to £250m
With Phase 2 option for further 700 units and £156m.
Novacyt increased Q production to 700 units a month. With the introduction of PROmate workflow 1.5 the upfront processing should be simplified and accelerate further adoption by UK and global clients imo
Pupils and teachers in England used to have to self-isolate if they had come into close contact with someone with confirmed covid.
Now those without symptoms can avoid quarantine if they agree to seven daily “lateral flow” tests, which give results in around 30 minutes. They only need to self-isolate if they test positive or develop symptoms as the week progresses.
Schools have already been given official guidance to start the new scheme, called “daily contact testing”, as a way of increasing face-to-face teaching.
But the Department of Health sent FactCheck an email on Tuesday evening which stated: “This programme is still a pilot at this stage and we will only roll this out once it has been deemed clinically safe and approved by the regulator.”
In an “updated” statement issued less than four hours later, this line and any reference to “pilots” were removed – and the Department has not given us an explanation why.
So while the scheme took effect on 4 January, it’s not clear whether the Department got the safety assurances and regulatory approval it said it needed beforehand.
And we don’t know whether the pilots that were carried out answered the vital question of whether the new plan might actually increase the spread of the virus.
‘Increase in transmission risk’
As FactCheck reported last month – and as the government has since confirmed – lateral flow tests only pick up around 60 per cent of cases when carried out by non-experts, though the chances of catching a positive case may improve with repeated tests.
When the possibility of replacing quarantine for contacts of anyone who tests positive with daily lateral flow tests was discussed at SAGE in mid-November, the scientists warned that it carried “a small increase in transmission risk”.
The fear was that even repeated testing might allow some positive cases to slip through, so the policy would not be as effective as making people self-isolate after coming into contact with a confirmed covid case.
The experts from SAGE urged ministers to carry out pilots before changing policy. They said the pilot “should enable evaluation of the potential of the system against different desired outcomes (e.g. reductions in the current quarantine period to enable people to get back to work, reductions in transmission, behavioural outcomes such as adherence to self-isolation), and to understand operational issues”.
The Department of Health and Social Care told FactCheck that it trialled daily contact testing in 12 schools in England and two in Northern Ireland.
It told us that the pilots looked at the practical elements of rolling of the programme.
But despite repeated requests, the government hasn’t provided us with any evidence that the pilots looked at the effect of the scheme on virus transmission.
Has it been ‘deemed clinically safe’?
We first approached the Department on Monday with questions about the evidence for the new policy.
It issued the following sta
Lse says £2m buys, £1m sells. What data are you seeing?